Tudor Investment Corp ET AL Sells 145,515 Shares of Theravance Biopharma, Inc. $TBPH

Key Points

• Tudor Investment Corp ET AL cut its stake in Theravance by 74.0%, selling 145,515 shares in Q3 and leaving 51,048 shares valued at about $745,000 (institutional ownership ~99.1%).
• Theravance SVP Rhonda Farnum sold 31,067 shares on March 16 (an 11.78% reduction of her holding); insiders now own roughly 6.9% of the stock.
• Analyst signals are mixed but tilted positive — Zacks and Wall Street Zen upgraded TBPH to Strong‑Buy and HC Wainwright raised its target to $27, while Pomerantz LLP has launched an investor investigation that could increase legal risk and volatility.

Tudor Investment Corp ET AL cut its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 74.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 51,048 shares of the biopharmaceutical company's stock after selling 145,515 shares during the period. Tudor Investment Corp ET AL owned 0.10% of Theravance Biopharma worth $745,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. CIBC Private Wealth Group LLC increased its position in shares of Theravance Biopharma by 20,269.6% during the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company's stock valued at $68,000 after buying an additional 4,662 shares during the period. CIBC Bancorp USA Inc. bought a new position in shares of Theravance Biopharma in the third quarter worth approximately $149,000. Caitong International Asset Management Co. Ltd increased its position in shares of Theravance Biopharma by 107.4% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company's stock worth $40,000 after purchasing an additional 1,411 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its position in shares of Theravance Biopharma by 100.9% in the third quarter. Jacobs Levy Equity Management Inc. now owns 40,538 shares of the biopharmaceutical company's stock worth $592,000 after purchasing an additional 20,364 shares during the last quarter. Finally, PharVision Advisers LLC bought a new position in shares of Theravance Biopharma in the third quarter worth approximately $157,000. 99.10% of the stock is currently owned by institutional investors.

Theravance Biopharma Price Performance

Shares of NASDAQ TBPH opened at $16.60 on Wednesday. Theravance Biopharma, Inc. has a one year low of $8.33 and a one year high of $21.03. The firm's 50 day simple moving average is $16.62 and its two-hundred day simple moving average is $17.11. The stock has a market capitalization of $854.73 million, a P/E ratio of 8.18 and a beta of 0.17.

Insider Buying and Selling

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $13.96, for a total transaction of $433,695.32. Following the transaction, the senior vice president directly owned 232,699 shares in the company, valued at $3,248,478.04. This trade represents a 11.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.90% of the stock is owned by insiders.

More Theravance Biopharma News

Here are the key news stories impacting Theravance Biopharma this week:

• Positive Sentiment: Zacks Research sharply raised multi-quarter and full‑year EPS forecasts for TBPH (notably FY2026 raised to $0.80 from a prior loss estimate and FY2027 to $0.28), and reiterated a "Strong-Buy" view — an across‑the‑board upgrade to near‑term profitability that can support higher valuation and buying interest. Zacks Research coverage summary
• Positive Sentiment: Wall Street Zen upgraded TBPH to "Strong‑Buy", adding independent positive analyst sentiment which can boost investor confidence and momentum. Theravance Biopharma Rating Increased to Strong-Buy at Wall Street Zen
• Negative Sentiment: Pomerantz LLP issued an investor alert saying it is investigating claims on behalf of Theravance investors — a potential securities litigation risk that can increase uncertainty, legal costs and volatility for the stock. Pomerantz investor alert

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on TBPH shares. Zacks Research upgraded shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Thursday, March 19th. BTIG Research restated a "buy" rating and issued a $21.00 price objective on shares of Theravance Biopharma in a research report on Friday, March 20th. Weiss Ratings cut shares of Theravance Biopharma from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Friday. HC Wainwright upped their price objective on shares of Theravance Biopharma from $20.00 to $27.00 and gave the stock a "buy" rating in a research report on Monday, March 2nd. Finally, Wall Street Zen upgraded shares of Theravance Biopharma from a "buy" rating to a "strong-buy" rating in a research report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $21.83.

Theravance Biopharma Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.

Want to see what other hedge funds are holding TBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.